Filter
1676
Filtered Results: 1676
Text search:
registration
of
drugs
Featured
Recommendations
144
New Publications
558
Language
Document type
No document type
1151
Guidelines
189
Studies & Reports
170
Manuals
63
Strategic & Response Plan
61
Training Material
17
Situation Updates
10
Fact sheets
10
Resource Platforms
4
Brochures
1
Countries / Regions
India
162
Kenya
72
Sierra Leone
46
Uganda
45
Nigeria
44
Nepal
43
Ethiopia
41
South Africa
41
Ghana
40
Rwanda
38
Malawi
35
Tanzania
33
Liberia
32
Bangladesh
31
Western and Central Europe
31
Global
31
Myanmar / Burma
27
Zambia
24
Namibia
23
Africa
23
Ukraine
22
Botswana
19
Philippines
17
Eastern Europe
17
Latin America and the Carribbean
16
Zimbabwe
15
Syria
15
Cambodia
14
Indonesia
13
Lesotho
13
South Sudan
12
Asia
12
Mozambique
11
South–East Asia Region
11
Congo, Democratic Republic of
9
Senegal
6
Pakistan
6
Eswatini/ Swaziland
6
Colombia
6
Russia
6
Tajikistan
5
Haiti
4
Jordan
4
Lebanon
4
Sudan
4
Benin
4
East and Southern Africa
4
Eastern Europe and Central Asia
4
Albania
4
Cameroon
3
Iraq
3
Afghanistan
3
Germany
3
Brazil
3
North Macedonia
3
Sri Lanka
3
West and Central Africa
3
Venezuela
3
Moldova
3
Iran
3
Georgia
3
Burkina Faso
2
Saudi Arabia
2
Argentina
2
Greece
2
Libya
2
Angola
2
Chile
2
Middle East and North Africa
2
Bhutan
2
Palestine
2
Armenia
2
Laos
2
Turkmenistan
2
Guinea-Bissau
1
Côte d’Ivoire / Ivory Coast
1
Morocco
1
USA
1
Somalia
1
Egypt
1
Thailand
1
Gambia
1
China
1
Malaysia
1
Ireland
1
Singapore
1
Papua New Guinea
1
Central African Republic
1
Peru
1
Ecuador
1
Bolivia
1
Madagascar
1
Yemen
1
Paraguay
1
Fiji
1
Djibouti
1
Timor Leste/ East Timor
1
Qatar
1
Bulgaria
1
Lithuania
1
Uzbekistan
1
Kyrgyzstan
1
Australia
1
Kazakhstan
1
North America
1
Uruguay
1
Denmark
1
Maldives
1
Tunisia
1
United Kingdom
1
Authors & Publishers
Publication Years
Category
Countries
878
Clinical Guidelines
129
Public Health
71
Women & Child Health
60
Key Resources
34
Pharmacy & Technologies
28
Capacity Building
22
Toolboxes
TB
170
HIV
165
Pharmacy
74
Mental Health
71
AMR
70
COVID-19
53
Conflict
42
NTDs
34
Caregiver
33
Refugee
25
NCDs
23
Disability
22
Rapid Response
15
Global Health Education
13
Ebola
10
Natural Hazards
10
Specific Hazards
8
Planetary Health
8
Polio
4
Health Financing Toolbox
4
Cholera
3
Zika
3
Social Ethics
3
South Sudan
2
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
A Snapshot of European Collection Schemes
SHOPS and HIA finalized a scope of work with USAID Senegal in April 2015, and a team of five private sector experts conducted the onsite assessments between May and June 2015. The Private Sector Ass...
Global UNIDO Project: Strengthening the local production of essential medicines in least developed and developing countries
This guidance should be followed if an unlicensed medicine is prepared in
a registered pharmacy. The preparation of an unlicensed medicine (for
example unlicensed methadone, or menthol in aqueous cream) in a pharmacy is called ‘extemporaneous ...
Antibiotic resistance (ABR) particularly hits resource poor countries, and is fuelled by irrational antibiotic (AB) prescribing. We surveyed knowledge, attitudes and practices of AB prescribing among medical students and doctors in Kisangani, DR Con...
Good Manufacturing Practice (GMP) describes a set of principles and procedures that, when followed, ensure that medicines and related substances are of high quality, safety and efficacy. SAHPRA is a...
Communication to Healthcare Professionals Mar-2020
This guideline is intended to assist healthcare professionals in the participation of very important process of continuous surveillance ... safety and efficacy of the health products which are used in their clinical practice. Continuous evaluation of medicines’ benefit and harm help to achieve the ultimate goal of safe and effective treatments available to patients.
The guideline is intended to assist healthcare professionals in the reporting of suspected adverse drug reactions (ADRs) associated with the use of all registered health products, including medicines, old medicines, medical devices and in-vitro diagnostics (IVDs).
This CPD Policy relates to all health professionals in the four Health Professional Councils in Rwanda namely; RMDC, NCNM, RAHPC, and RPC. The policy requires all health professionals to participate in the CPD Programs. The purpose of this CPD Polic...
PMPB/INS-GUIDE/01
Specific measures are being taken within the National Tuberculosis Control Programme (NTP) to address the MDR TB problem through appropriate management of patients and strategies to prevent the propagation and dissemination ... MDR TB.
The term "Programmatic Management of Drug Resistant TB" (PMDT) refers to programme based MDR TB diagnosis, management and treatment. This guideline promotes full integration of basic TB control and PMDT activities under the NTP, so that patients with TB are evaluated for drug resistance and are placed on the appropriate treatment regimen and properly managed from the outset of treatment, or as early as possible. The guidelines also integrate the identification and treatment of more severe forms of drug resistance, such as extensively drug resistant TB (XDR TB).
At the end, the guideline introduces new standards for registering, monitoring and reporting outcomes of multidrug resistant TB cases.
The term "Programmatic Management of Drug Resistant TB" (PMDT) refers to programme based MDR TB diagnosis, management and treatment. This guideline promotes full integration of basic TB control and PMDT activities under the NTP, so that patients with TB are evaluated for drug resistance and are placed on the appropriate treatment regimen and properly managed from the outset of treatment, or as early as possible. The guidelines also integrate the identification and treatment of more severe forms of drug resistance, such as extensively drug resistant TB (XDR TB).
At the end, the guideline introduces new standards for registering, monitoring and reporting outcomes of multidrug resistant TB cases.
The Democratic Republic of Timor-Leste has the highest TB incidence rate in the South East Asian Region - 498 per 100,000, which is the seventh highest in the world. In Timor-Leste TB is the eighth most common cause ... death.
The salient observations are as follows:
In 2018, 487 (12.5%) of the 3906 notified TB patients were tested for RR-TB and only 12 lab confirmed RR-TB patients were initiated on standard MDR-TB treatment of 20-months duration, (a 3-fold increase in RR-TB detection compared with 2017). This amounts to treatment coverage of only 17% of 72 estimated MDR/RR-TB among notified TB patients (3906) and 5% of 240 estimated incident MDR-TB patients as compared to 62% treatment coverage of 6300 incident drug sensitive TB patients estimated in TLS. The treatment success in the 2016 annual cohort of 6 MDR-TB patients has been reported at 83%. 80% of TB patients know their HIV Status with around 1% TB-HIV co-infection, 37/ 77 (48%) TB-HIV Co-infection Detected. Of the 387 PLHIV currently alive on ART, exact status on TB screening and testing is unknown. % of PLHIV newly enrolled in HIV care who received IPT is not known.
In 2018, the mortality rate for TB was 94 deaths per 100,000 people (1200 per annum) in TL with an increasing mortality trend (Figure 1), despite TB services being available for nearly two decades.
A survey of catastrophic costs due to TB (2016) highlights that 83% of TB patients are reported to be facing catastrophic costs due to the disease. This is the highest rate in the world.
Report of a mission 20–24 April 2015
Health, Rights and Drugs
recommended
Harm Reducation, Decriminalization and Zero Discrimination for People who use Drugs
